IRIX Stock Overview
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
IRIDEX Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.03 |
| 52 Week High | US$3.65 |
| 52 Week Low | US$1.31 |
| Beta | 0.82 |
| 1 Month Change | 16.99% |
| 3 Month Change | 13.48% |
| 1 Year Change | 33.49% |
| 3 Year Change | -65.45% |
| 5 Year Change | -35.81% |
| Change since IPO | -70.44% |
Recent News & Updates
Iridex's Strategic Review Process Should Bear Fruit 'Soon'
Mar 28Little Excitement Around IRIDEX Corporation's (NASDAQ:IRIX) Revenues
Feb 14
Recent updates
Iridex's Strategic Review Process Should Bear Fruit 'Soon'
Mar 28Little Excitement Around IRIDEX Corporation's (NASDAQ:IRIX) Revenues
Feb 14Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?
Oct 04Lacklustre Performance Is Driving IRIDEX Corporation's (NASDAQ:IRIX) 32% Price Drop
Aug 12Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?
Apr 14We're Hopeful That IRIDEX (NASDAQ:IRIX) Will Use Its Cash Wisely
Oct 12Is IRIDEX (NASDAQ:IRIX) Using Too Much Debt?
Feb 25Iridex To Benefit From New Revolutionary Glaucoma Treatment
Jan 11Analysts Expect Breakeven For IRIDEX Corporation (NASDAQ:IRIX) Before Long
Jan 03IRIDEX says laser therapy now accepted in the European Glaucoma Society guidelines
Dec 23Shareholder Returns
| IRIX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -4.7% | 1.4% | 1.2% |
| 1Y | 33.5% | -0.7% | 24.7% |
Return vs Industry: IRIX exceeded the US Medical Equipment industry which returned -0.7% over the past year.
Return vs Market: IRIX exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| IRIX volatility | |
|---|---|
| IRIX Average Weekly Movement | 10.2% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IRIX has not had significant price volatility in the past 3 months.
Volatility Over Time: IRIX's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 111 | David Bruce | www.iridex.com |
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders.
IRIDEX Corporation Fundamentals Summary
| IRIX fundamental statistics | |
|---|---|
| Market cap | US$49.25m |
| Earnings (TTM) | -US$9.57m |
| Revenue (TTM) | US$51.87m |
0.9x
P/S Ratio-5.1x
P/E RatioIs IRIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IRIX income statement (TTM) | |
|---|---|
| Revenue | US$51.87m |
| Cost of Revenue | US$30.06m |
| Gross Profit | US$21.81m |
| Other Expenses | US$31.38m |
| Earnings | -US$9.57m |
Last Reported Earnings
Dec 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.59 |
| Gross Margin | 42.04% |
| Net Profit Margin | -18.45% |
| Debt/Equity Ratio | 0% |
How did IRIX perform over the long term?
See historical performance and comparison